Publications by authors named "Jouni Silvennoinen"
Limited data is available on vedolizumab combination therapies in real-world clinical practice. Here, we evaluated the concomitant corticosteroid, immunosuppressive, and 5-aminosalicylic acid utilization of inflammatory bowel disease (IBD) patients treated with vedolizumab in a nationwide, retrospective, non-interventional, multi-centre chart review study. All adult patients from 27 Finnish gastroenterology centres with a diagnosis of Crohn's disease (CD) or ulcerative colitis (UC) who had at least one vedolizumab infusion since it's availability in Finland were included in the study.
View Article and Find Full Text PDFObjectives: The efficacy and tolerability of vedolizumab in the treatment of inflammatory bowel diseases (IBD) has been demonstrated in an extensive GEMINI clinical trial programme. Clinical trials represent highly selected patient populations and, therefore, it is important to demonstrate effectiveness in real-life clinical practice. We set out to assess real-world treatment outcomes of vedolizumab in a nationwide cohort of treatment refractory Finnish Crohn's disease (CD) and ulcerative colitis (UC) patients.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted to compare the effectiveness and safety of taking prolonged-release mesalamine once daily versus twice daily in patients with mild-to-moderate ulcerative colitis.
- The trial involved 362 patients and found that 70.9% of those taking 2 g once daily maintained remission after one year compared to 58.9% of those taking 1 g twice daily, showing significant improvement with the once-daily regimen.
- Additionally, adherence to therapy was better in the once-daily group, and overall side effects were similar between both dosing schedules, suggesting that once-daily mesalamine is a more effective and preferred option for maintaining remission in these patients.